Health Condition 1: B440- Invasive pulmonary aspergillosis
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
Dr Gatadi K Sumedh
Eligibility
Inclusion criteria
Inclusion criteria: 1)Adult patients 18 years or above currently receiving voriconazole for 5 consecutive days for antifungal prophylaxis or treatment 2)Those willing to give written informed consent
Exclusion criteria
Exclusion criteria: 1)Known poor compliance with voriconazole regimen. 2)If participated in other study in the past three months. 3)Participants on Phenytoin and Rifampicin will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •Proportion of patients achieving therapeutic voriconazole trough concentrations across different CYP2C19 genotype categories (poor, intermediate, extensive, ultra-rapid metabolizers)Timepoint: Trough sample will be collected | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Proportion of patients having adverse events 2)To evaluate the predictive performance of the Bayesian dosing model by assessing the accuracy & precision of model-predicted voriconazole plasma concentrations as compared to observed concentrations. 3)Percentage of patients achieving therapeutic trough concentrations (1to5.5 µg per mL) using model informed dosing. 4)Comparison of target attainment between Bayesian model guided dosing (simulation) & standard empirical dosing. Timepoint: Single trough level | — |
Countries
India
Contacts
Public ContactC Prabhakar Reddy
Nizams Institute of Medical Sciences
Outcome results
None listed